Ticker brief
UTHR UNITED THERAPEUTICS CORP
Consumer, Non-cyclical · Biotechnology
last close
$515.46
1 day
-2.4%
14 days
+3.1%
mkt cap
$23.6B
signals 14d
9
authors 14d
8
crowd 14d
+1.5σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 32% | IV/HV 1.05× |
| Skew — 25Δ RR 30d | -0.032 | 25Δ call IV − put IV |
| OI alarm | quiet | last alarm 2026-05-07 (z=5.2) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-14 → 2026-08-27 · now +0.38 (−1 bearish … +1 bullish)
Who spoke8
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @DeepValuePlay | B | -0.70 | 2 | -0.25 |
| @AponiaAnalytics | B | +4.91 | 1 | +0.35 |
| @SayNoToTrading | A | -0.52 | 1 | +0.00 |
| @schaeffers | C | +3.18 | 1 | +0.00 |
| @PSInvestor | B | -1.48 | 1 | +0.15 |
| @OzmosiHealth | C | · | 1 | +0.40 |
| @semodough | C | -3.01 | 1 | +0.40 |
| @Biotech2k1 | A | +1.02 | 1 | +0.35 |
Recent signals9of 9 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-27 | @Biotech2k1 | +0.35 | Cites strong supportive treprostinil data across four indications. | -2.4% | tweet ↗ |
| 2026-08-27 | @semodough | +0.40 | Cantor reiterates a strongly bullish UTHR view based on IPF and PPF despite flat 2026 growth. | -2.4% | tweet ↗ |
| 2026-08-24 | @OzmosiHealth | +0.40 | FDA accepted United Therapeutics' new drug application for ralinepag. | +0.5% | tweet ↗ |
| 2026-08-24 | @PSInvestor | +0.15 | Reports FDA 510(k) clearance for TEM's ECG-PH AI device and explains its clinical scope and UTHR partnership. | +0.5% | tweet ↗ |
| 2026-08-17 | @schaeffers | +0.00 | Reports unusually high options-volume multiples and call-heavy activity in PSX and RUM. | +1.4% | tweet ↗ |
| 2026-08-17 | @SayNoToTrading | +0.00 | Author argues Renaissance's short-horizon 13F provides little investment insight. | +1.4% | tweet ↗ |
| 2026-08-17 | @AponiaAnalytics | +0.35 | TETON-PPF completed enrollment, setting up a 2H27 readout and potential market expansion. | +1.4% | tweet ↗ |
| 2026-08-14 | @DeepValuePlay | -0.25 | Argues Yutrepia should clear exclusivity issues and ultimately obtain FDA approval. | +3.1% | tweet ↗ |
| 2026-08-14 | @DeepValuePlay | -0.25 | Says Yutrepia's dosing and side-effect profile should overcome UTHR exclusivity despite likely litigation. | +3.1% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.